ARA 290 vs Tesamorelin
Updated July 23, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of ARA 290 and Tesamorelin (also searched as Tesamorelin vs ARA 290) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
ARA 290 centers on neuro, while Tesamorelin leans toward metabolic. On indexed research, Tesamorelin is ahead (ARA 290: 4 studies, Preclinical; Tesamorelin: 5, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •ARA 290 is strongest for neuro; Tesamorelin for metabolic.
- •Evidence: ARA 290 Preclinical (4 studies) vs Tesamorelin Human clinical (5).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
Tissue-Protective Peptide | Innate Repair Receptor Agonist
GHRH Analog | Visceral Fat Reduction
ARA 290 vs Tesamorelin: side-by-side
| Metric | ARA 290 | Tesamorelin |
|---|---|---|
| Class | Healing | GH |
| Regulatory status | Research use only | FDA-approved |
| Evidence grade | Preclinical | Human clinical |
| Studies indexed | 4 | 5 |
| Research level | Extensively Studied | FDA Approved |
| Strongest effect | Neuro & mood | Metabolic & appetite |
| Healing & recovery | 2.3▲ | 1.0 |
| Muscle & body comp | 2.2▲ | 2.0 |
| Metabolic & appetite | 1.7 | 4.0▲ |
| Neuro & mood | 3.0▲ | 1.0 |
| Sleep & circadian | 1.0▲ | 0.0 |
| Inflammation & immune | 2.7▲ | 1.0 |
| Skin & aesthetics | 2.2 | 3.0▲ |
▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).
Mechanism & pharmacokinetics
| Property | ARA 290 | Tesamorelin |
|---|---|---|
| Mechanism | — | GHRH analog |
| Route | — | Subcutaneous injection |
| Half-life | — | ~26–38 min |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Tesamorelin?
### Tesamorelin Summary Tesamorelin is a synthetic peptide that functions as a growth hormone-releasing hormone (GHRH) analog, primarily investigated for its potential to reduce visceral fat in individuals with HIV-associated lipodystrophy. Its role in metabolic health and body composition continues to be explored in various clinical contexts.
Full Tesamorelin profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | ARA 290 | 2.3/5 effect signal |
| Muscle | ARA 290 | 2.2/5 effect signal |
| Metabolic | Tesamorelin | 4.0/5 effect signal |
| Neuro | ARA 290 | 3.0/5 effect signal |
| Sleep | ARA 290 | 1.0/5 effect signal |
| Inflammation | ARA 290 | 2.7/5 effect signal |
| Skin | Tesamorelin | 3.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack ARA 290 and Tesamorelin?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
ARA 290 vs Tesamorelin: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
ARA 290 has 4 approved studies indexed (Preclinical), and Tesamorelin has 5 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is ARA 290 or Tesamorelin better?
It depends on your goal. ARA 290 is strongest for neuro; Tesamorelin for metabolic. Tesamorelin has more indexed studies (5). See the goal-by-goal breakdown above.
Is ARA 290 or Tesamorelin better for weight loss?
Tesamorelin shows the stronger metabolic & appetite profile (4.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.
Is ARA 290 or Tesamorelin better for muscle?
ARA 290 leads on the muscle & body-composition axis (2.2/5).
Which has more research, ARA 290 or Tesamorelin?
ARA 290 has 4 approved studies indexed (Preclinical); Tesamorelin has 5 (Human clinical). Higher counts mean more to read, not proven superiority.
Can you stack ARA 290 and Tesamorelin?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of ARA 290 vs Tesamorelin?
ARA 290: no community-reported effects logged yet. Tesamorelin: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is ARA 290 or Tesamorelin FDA-approved?
ARA 290 is a research-use compound and is not FDA-approved. Tesamorelin is FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Tesamorelin better than ARA 290?
For metabolic, Tesamorelin has the edge; for neuro, ARA 290 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 23, 2026.